Suppr超能文献

欧洲参考网络:挑战与机遇。

European Reference Networks: challenges and opportunities.

作者信息

Tumiene Birute, Graessner Holm, Mathijssen Irene Mj, Pereira Alberto M, Schaefer Franz, Scarpa Maurizio, Blay Jean-Yves, Dollfus Helene, Hoogerbrugge Nicoline

机构信息

Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

出版信息

J Community Genet. 2021 Apr;12(2):217-229. doi: 10.1007/s12687-021-00521-8. Epub 2021 Mar 17.

Abstract

European Reference Networks (ERNs) were founded on the principle that many rare disease (RD) issues are pan-European and any single Member State cannot solve them alone. In 2021, ERNs are already in the deployment stage; however, their day-to-day functioning and realization of their potential are still severely hampered by many challenges, including issues in governance and regulation, lack of legal status, insufficient and unsustainable funding, lack of ERN integration into national systems, endangered collaboration with UK RD experts due to Brexit, insufficient exploitation of ERN potential in RD research, underappreciation of highly qualified human resources, problems with the involvement of patient representatives, and still unclear place of ERNs in the overall European RD and digital ecosystem. Bold and innovative solutions that must be taken to solve these challenges inevitably involve pan-European collaboration across several sectors and among multistakeholder RD communities and in many cases crucially rely on the constructive dialogue and coherent, united decisions of national and European authorities that are based on common EU values. Importantly, unresolved challenges may have a strong impact on the further sustainability of ERNs and their ability to realize full potential in addressing huge unmet needs of RD patients and their families.

摘要

欧洲参考网络(ERNs)基于这样一个原则建立:许多罕见病问题是泛欧洲的,任何单个成员国都无法独自解决这些问题。2021年,ERNs已进入部署阶段;然而,它们的日常运作及其潜力的实现仍受到诸多挑战的严重阻碍,包括治理和监管问题、缺乏法律地位、资金不足且不可持续、ERNs未融入国家体系、脱欧导致与英国罕见病专家的合作受到威胁、在罕见病研究中对ERNs潜力的利用不足、对高素质人力资源的重视不够、患者代表参与方面的问题,以及ERNs在整个欧洲罕见病和数字生态系统中的地位仍不明确。解决这些挑战必须采取的大胆创新解决方案不可避免地涉及多个部门以及多方利益相关者罕见病群体之间的泛欧洲合作,而且在许多情况下,关键依赖于基于欧盟共同价值观的国家和欧洲当局之间的建设性对话以及一致、统一的决策。重要的是,未解决的挑战可能会对ERNs的进一步可持续性及其在满足罕见病患者及其家庭巨大未满足需求方面充分发挥潜力的能力产生重大影响。

相似文献

1
European Reference Networks: challenges and opportunities.
J Community Genet. 2021 Apr;12(2):217-229. doi: 10.1007/s12687-021-00521-8. Epub 2021 Mar 17.
3
Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases.
Eur J Hum Genet. 2021 Sep;29(9):1325-1331. doi: 10.1038/s41431-021-00859-0. Epub 2021 Jun 1.
4
The European Reference Network for Rare Neurological Diseases.
Front Neurol. 2021 Jan 14;11:616569. doi: 10.3389/fneur.2020.616569. eCollection 2020.
5
ERN BOND: The key European network leveraging diagnosis, research, and treatment for rare bone conditions.
Eur J Med Genet. 2024 Apr;68:104916. doi: 10.1016/j.ejmg.2024.104916. Epub 2024 Feb 1.
7
Together4RD position statement on collaboration between European reference networks and industry.
Orphanet J Rare Dis. 2023 Sep 5;18(1):272. doi: 10.1186/s13023-023-02853-9.
8
European Reference Networks and Guideline Development and Use: Challenges and Opportunities.
Public Health Genomics. 2015;18(5):318-20. doi: 10.1159/000435852. Epub 2015 Jul 23.

引用本文的文献

2
Pediatric to adult care transfer in rare liver diseases: Recommendations based on insights from a European omnistakeholder event.
JHEP Rep. 2025 Mar 26;7(6):101403. doi: 10.1016/j.jhepr.2025.101403. eCollection 2025 Jun.
6
Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE).
ESMO Open. 2025 Feb;10(2):104126. doi: 10.1016/j.esmoop.2024.104126. Epub 2025 Jan 27.
7
[The European Rare Kidney Disease Reference Network].
Inn Med (Heidelb). 2024 Dec;65(12):1283-1292. doi: 10.1007/s00108-024-01810-3. Epub 2024 Nov 13.
8
Mapping the diagnostic odyssey of congenital disorders of glycosylation (CDG): insights from the community.
Orphanet J Rare Dis. 2024 Nov 1;19(1):407. doi: 10.1186/s13023-024-03389-2.

本文引用的文献

1
Whole-genome sequencing of patients with rare diseases in a national health system.
Nature. 2020 Jul;583(7814):96-102. doi: 10.1038/s41586-020-2434-2. Epub 2020 Jun 24.
2
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.
Eur J Hum Genet. 2020 Feb;28(2):165-173. doi: 10.1038/s41431-019-0508-0. Epub 2019 Sep 16.
3
Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts.
Nat Med. 2019 Jun;25(6):911-919. doi: 10.1038/s41591-019-0457-8. Epub 2019 Jun 3.
5
Is there a fair allocation of healthcare research funds by the European Union?
PLoS One. 2019 Apr 15;14(4):e0207046. doi: 10.1371/journal.pone.0207046. eCollection 2019.
6
Impact of centralization of services on outcomes in a rare tumour: Retroperitoneal sarcomas.
Eur J Surg Oncol. 2019 Feb;45(2):249-253. doi: 10.1016/j.ejso.2018.06.032. Epub 2018 Jul 10.
7
Is it research or is it clinical? Revisiting an old frontier through the lens of next-generation sequencing technologies.
Eur J Med Genet. 2018 Oct;61(10):634-641. doi: 10.1016/j.ejmg.2018.04.009. Epub 2018 Apr 25.
8
The 100 000 Genomes Project: bringing whole genome sequencing to the NHS.
BMJ. 2018 Apr 24;361:k1687. doi: 10.1136/bmj.k1687.
9
Patient reported outcome measures in rare diseases: a narrative review.
Orphanet J Rare Dis. 2018 Apr 23;13(1):61. doi: 10.1186/s13023-018-0810-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验